title: [CD44 expression: a new prognostic factor in neuroblastoma].
abstract: CD44 gene products are potential markers of aggressiveness in different tumor models, a result which prompted us to study clinical neuroblastoma (NB) specimens. CD44 expression was determined by immunostaining of 52 NB with a monoclonal antibody (J173) directed against an epitope common to all CD44 isoforms. All tumors were from patients (pts) with newly diagnosed NB treated with standardized protocols. They were classified according to international criteria [11]. CD44 immunoreactivity was detected in 37 tumors (71%). CD44 was expressed in 100% of favorable NB stages (1, 2 or 4S), but only 50% of advanced NB (stages 3 and 4) (p = 0.0001), suggesting that the absence rather that the overexpression of CD44 is a signal of tumor aggressiveness. The cumulative event-free survival was significantly longer in pts with CD44-positive tumors as compared to pts with CD44-negative tumors (p < 10(-5)). More importantly, progression-free survival was also significantly higher in CD44-positive pts within the high-risk group (p < 0.01). In univariate analyses, we tested the prognostic value of tumor expression of CD44 in comparison with tumor stage, age, tumor histology and presence or absence of N-myc proto-oncogene amplification. All five measures had significant prognostic value. The expression of CD44 and the absence of N-myc amplification were the most powerful predictors of a favorable clinical outcome. In a multivariate analysis of these measures, CD44 expression and tumor stage were the only independent prognostic factors for the prediction of patient survival. NB is the first clinical model described in which tumor aggressiveness correlates with a repression rather than a stimulation of CD44 expression. We recommend the use of CD44 as an additional biological marker in the initial staging of neuroblastoma.
authors.affiliation: Laboratoire de biologie cellulaire, centre Léon-Bérard, Lyon, France.
authors.forename: V
authors.initials: V
authors.lastname: Combaret
authors.forename: C
authors.initials: C
authors.lastname: Lasset
authors.forename: R
authors.initials: R
authors.lastname: Bouvier
authors.forename: D
authors.initials: D
authors.lastname: Frappaz
authors.forename: P
authors.initials: P
authors.lastname: Thiesse
authors.forename: A C
authors.initials: AC
authors.lastname: Rebillard
authors.forename: T
authors.initials: T
authors.lastname: Philip
authors.forename: M C
authors.initials: MC
authors.lastname: Favrot
mesh_terms: D000293:Adolescent; D000704:Analysis of Variance; D000951:Antigens, Neoplasm / Q000032:analysis*; D015139:Blotting, Southern; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D018960:Hyaluronan Receptors / Q000032:analysis*; D007124:Immunoenzyme Techniques; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D009447:Neuroblastoma / Q000276:immunology* / Q000401:mortality; D011379:Prognosis; D000090063:Proto-Oncogene Mas
chemical_list: D000951:Antigens, Neoplasm; D018960:Hyaluronan Receptors; C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas